Fig. 5: RSV post-F antibody GMC through day 361 by treatment and medically attended, diagnostic-confirmed RSV infection. | Nature Medicine

Fig. 5: RSV post-F antibody GMC through day 361 by treatment and medically attended, diagnostic-confirmed RSV infection.

From: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants

Fig. 5: RSV post-F antibody GMC through day 361 by treatment and medically attended, diagnostic-confirmed RSV infection.

a, Phase 2b study post-F IgG antibodies. b, MELODY study post-F IgG antibodies. *P < 0.05, nirsevimab versus placebo with diagnostic-confirmed RSV; †P < 0.05, †††P < 0.001, nirsevimab versus placebo without diagnostic-confirmed RSV. n denotes number of infants who had a sample available at baseline. Data are presented as GMCs ± 95% CIs, which were calculated assuming log normal distribution. Two-sided P values were calculated from the F statistic from ANOVA, without adjustment. a, At day 91 without diagnostic-confirmed RSV, P = 0.0227, and at day 361 with diagnostic-confirmed RSV, P = 0.0458. b, At day 31 without diagnostic-confirmed RSV, P < 0.0001, and at day 361 with diagnostic-confirmed RSV, P = 0.0391.

Back to article page